3VG Stock Chart & Stats
€2.74
-€0.06(-8.12%)
At close: 4:00 PM EST
€2.74
-€0.06(-8.12%)
Day’s Range― - ―
52-Week Range€0.95 - €4.31
Previous CloseN/A
Volume0.00
Average Volume (3M)596.00
Market Cap
€51.54M
Enterprise Value€37.19M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€2.88M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume242
30 Day Avg. Volume596
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche CNS Focus And Partnership ModelTheranexus's focused strategy on CNS and rare neurological diseases concentrates R&D resources where unmet need and regulatory incentives can improve long-term program value. Leveraging partnerships reduces capital intensity, shares development risk, and can accelerate commercialization pathways, supporting durable program advancement over months.
Lower Debt From Prior PeaksA reduction in absolute debt versus prior peaks improves near-term financial flexibility and decreases fixed obligations. For a small clinical-stage biopharma, lower leverage reduces refinancing pressure and interest burden, making it easier to manage trial timelines and licensing negotiations over the coming quarters.
Improving Cash Burn TrendA narrowing of operating and free cash outflows indicates management has reduced cash intensity or slowed spending growth, strengthening runway prospects. Sustained improvement in cash burn reduces frequency and size of dilutive financings and supports more orderly program execution over the next several quarters.
Bears Say
Persistent UnprofitabilityContinued negative EBIT and EBITDA mean the company cannot internally fund development or scale operations. Persistent losses increase reliance on external capital, raise dilution risk, and limit ability to expand programs or invest in late-stage studies without material financing events over the medium term.
Revenue Collapse And Weak VisibilityA complete drop to zero revenue erodes commercial validation and removes predictable cash inflows. This materially heightens funding dependence, complicates forecasting, and raises execution risk for ongoing programs, making multi-quarter planning and investor confidence more fragile.
Balance-sheet Fragility And Funding RelianceEpisodes of negative equity followed by recovery signal accumulated losses and past dilution, underscoring balance-sheet fragility. The documented reliance on external financing creates execution and timing risk: future trials or milestones may require additional capital, increasing dilution risk and potential delays.
Theranexus SA News
3VG FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €0.95 and its highest was €4.31 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €51.54M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is Sep 24, 2026 which is in 75 days.
How were Theranexus SA’s earnings last quarter?
Currently, no data Available
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 14,472,778 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in DE:3VG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Technical Analysis
GenSight Biologics SA
―
AB Science SA
―
Sensorion SAS
―
Intrasense SA
―
MedinCell SA
―
Options Prices
Currently, No data available
---